Skip to content
Screener

Kyverna Therapeutics, Inc. KYTX Price / book

Price / book at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
5.3×-0.2×
Gilead Sciences logo
Gilead SciencesGILD
13.3×+6.5×
Climb Bio, Inc. logo
Climb Bio, Inc.CLYM
2.2×+1.8×
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
1.4×+1.1×
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
2.5×+1.6×
Allogene Therapeutics logo
Allogene TherapeuticsALLO
2.1×+1.3×

Other financials

Income statement

See full
Operating income-$41.4M+12.7%
Net income-$39.7M+11.0%
EPS (diluted)-$0.66+35.9%

Balance sheet

See full
Cash & equivalents$32.2M-43.4%
Total debt$9.2M+32.1%
Total equity$195.6M-12.7%
Total assets$257.0M-1.4%

Cash flow

See full
Operating cash flow-$41.6M+7.4%
CapEx$2.0K-98.0%
Free cash flow-$33.5M+10.8%

Valuation

See full
Market cap$483.93M+261%
Enterprise value$460.9M+433%

Returns & leverage

See full
Return on equity-74.5%+74.4pp
Debt / equity0×0.0×
Current ratio8.1×+0.7×

Where this comes from

Calculated from Kyverna Therapeutics, Inc.’s reported figures.

market cap/total stockholders equity=2.7×

Based on the most recent quarter.

The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026. Open the filing →

Filed
May 12, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219397

FAQ

What is Kyverna Therapeutics, Inc.'s price / book?
Kyverna Therapeutics, Inc. (KYTX) reported price / book of 2.7× in Q1 2026.
How has Kyverna Therapeutics, Inc.'s price / book changed year-over-year?
Kyverna Therapeutics, Inc.'s price / book increased by 617.1% year-over-year, from 0.4× to 2.7×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Kyverna Therapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude